Back to Search
SIREESHA DATLA MD
MD
Medical Oncology Physician
NPI: 1275819526IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
ME161713(FL)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
ME161713(FL)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
57785(AZ)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
263027(NY)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
263027(NY)
Education
OTHER
Class of 2006
Research & Publications (11)
Prevention of aortic elastic lamina defects by losartan in apolipoprotein(E)-deficient mouse.
PMID 19298535·Clin Exp Pharmacol Physiol·2009
7-preclinical
Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation.
PMID 19150879·Arterioscler Thromb Vasc Biol·2009
7-preclinical
Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro.
PMID 17717289·Arterioscler Thromb Vasc Biol·2007
8-other
Adventitial application of the NADPH oxidase inhibitor apocynin in vivo reduces neointima formation and endothelial dysfunction in rabbits.
PMID 17659266·Cardiovasc Res·2007
7-preclinical
Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress.
PMID 17679649·Hypertension·2007
7-preclinical
NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells.
PMID 16982957·Hypertension·2006
8-other
Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator.
PMID 16651004·Pharmacol Res·2006
4-observational
Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration.
PMID 16949828·Bioorg Med Chem·2006
7-preclinical
2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.
PMID 15326524·Org Biomol Chem·2004
7-preclinical
Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
PMID 15140637·Eur J Pharmacol·2004
4-observational
Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats.
PMID 12355578·Biopharm Drug Dispos·2002
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 5 locations total
- Address
- 450 Clarkson Ave # 1262
Brooklyn, NY 11203 - Phone
- (917) 291-1875
Locations (5)
Practice Location
450 Clarkson Ave # 1262, Brooklyn, NY
(917) 291-1875
Practice Location
1615 Pasadena Ave S Ste 400, South Pasadena, FL
(727) 341-1316
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
725 6TH AVE S STE 2200, ST PETERSBURG, FL
(727) 821-0017
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
5767 49TH ST N STE B, ST PETERSBURG, FL
(727) 522-0558
Practice Location
13188 N 103rd Dr Ste 201, Sun City, AZ
(804) 409-5514
Quick Facts
- NPI
- 1275819526
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 5
- Locations
- 5
- Years in Practice
- 20
- Publications
- 11
Are you this provider?
Claim Your Profile